Search Results

Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats

Authors: Kassan, M; Montero, MJ; Sevilla, MA

Source: British Journal of Pharmacology, Volume 158, Number 2, September 2009 , pp. 541-547(7)

Publisher: Blackwell Publishing

Development and Validation of Stability-Indicating HPLC Methods for Quantitative Determination of Pravastatin, Fluvastatin, Atorvastatin, and Rosuvastatin in Pharmaceuticals

Authors: Gomes, Fabio Pereira; Garcia, Pedro Lopez; Porto Alves, Joao; Singh, Anil Kumar; Kedor-Hackmann, Erika Rosa Maria; Miritello Santoro, Maria Ines

Source: Analytical Letters, Volume 42, Number 12, 2009 , pp. 1784-1804(21)

Publisher: Taylor and Francis Ltd

Evidence-Based Medical Therapy of Patients with Acute Coronary Syndromes

Authors: Ramanath, Vijay S.; Eagle, Kim A.

Source: American Journal of Cardiovascular Drugs, Volume 7, Number 2, 2007 , pp. 95-116(22)

Publisher: Adis International

The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin

Authors: Rakotoniaina, Zo; Guerard, Pascal; Lirussi, Frederic; Goirand, Françoise; Rochette, Luc; Dumas, Monique; Bardou, Marc

Source: Naunyn-Schmiedeberg's Archives of Pharmacology, Volume 374, Number 3, December 2006 , pp. 195-206(12)

Publisher: Springer

The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS

Authors: Guerard, Pascal; Rakotoniaina, Zo; Goirand, Françoise; Rochette, Luc; Dumas, Monique; Lirussi, Frederic; Bardou, Marc

Source: Naunyn-Schmiedeberg's Archives of Pharmacology, Volume 373, Number 6, September 2006 , pp. 401-414(14)

Publisher: Springer

Hydroxymethylglutaryl co-enzyme A reductase inhibition attenuates endotoxin-mediated inflammatory responses

Authors: Joyce, M.; Casey, R.; Gang, C.; Winter, D.; Kelly, C. J.; Bouchier-Hayes, D. J.

Source: British Journal of Surgery, Volume 92, Number 8, August 2005 , pp. 1034-1040(7)

Publisher: John Wiley & Sons, Ltd.

Effects of statins on myocardial and coronary artery response to ischemia-reperfusion

Authors: Rendig S.V.; Symons J.D.; Amsterdam E.A.

Source: Canadian Journal of Physiology and Pharmacology, Volume 81, Number 11, 1 November 2003 , pp. 1064-1071(8)

Publisher: NRC Research Press

Pilot study examining the effect of cholesterol lowering on platelet nitric oxide responsiveness and arterial stiffness in subjects with isolated mild hypercholesterolaemia

Authors: Stepien J.M.; Prideaux R.M.; Willoughby S.R.; Chirkov Y.Y.; Horowitz J.D.

Source: Clinical and Experimental Pharmacology and Physiology, Volume 30, Number 7, July 2003 , pp. 507-512(6)

Publisher: Blackwell Publishing

Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin

Authors: Nezasa K.; Higaki K.; Takeuchi M.; Nakano M.; Koike M.

Source: Xenobiotica, Volume 33, Number 4, April 2003 , pp. 379-388(10)

Publisher: Informa Healthcare

Pravastatin sodium, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases serum total cholesterol in Japanese White rabbits by two different mechanisms

Authors: Miyazaki A.; Koga T.

Source: Atherosclerosis, Volume 162, Number 2, June 2002 , pp. 299-306(8)

Publisher: Elsevier

Influence of high cholesterol diet and pravastatin sodium on the initiation of liver regeneration in rats after partial hepatectomy

Authors: Zivna H.; Zivny P.; Palicka V.; Simakova E.

Source: Nutrition, Volume 18, Number 1, January 2002 , pp. 51-55(5)

Publisher: Elsevier

Fluorescein uptake by a monocarboxylic acid transporter in human intestinal Caco-2 cells

Authors: Kuwayama K.; Miyauchi S.; Tateoka R.; Abe H.; Kamo N.

Source: Biochemical Pharmacology, Volume 63, Number 1, 1 January 2002 , pp. 81-88(8)

Publisher: Elsevier

Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis

Authors: Johnston T.P.; Nguyen L.B.; Chu W.A.; Shefer S.

Source: International Journal of Pharmaceutics, Volume 229, Number 1, 28 October 2001 , pp. 75-86(12)

Publisher: Elsevier

Chromatographic purification of some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

Authors: Grahek R.; Milivojevic D.; Bastarda A.; Kracun M.

Source: Journal of Chromatography A, Volume 918, Number 2, 25 May 2001 , pp. 319-324(6)

Publisher: Elsevier

Antioxidative effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxidation of phospholipid liposomes

Authors: Yamamoto A.; Ichihara K.; Hoshi K.

Source: Journal of Pharmacy and Pharmacology, Volume 53, Number 2, 1 February 2001 , pp. 227-232(6)

Publisher: Pharmaceutical Press

Clinical Pharmacokinetics of Pravastatin: Mechanisms of Pharmacokinetic Events

Author: Hatanaka T.

Source: Clinical Pharmacokinetics, Volume 39, Number 6, December 2000 , pp. 397-412(16)

Publisher: Adis International

Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients

Authors: Miossec, P.; Zkhiri, F.; Pariès, J.; David-Dufilho, M.; Devynck, M. A.; Valensi, P. E.

Source: Diabetic Medicine, Volume 16, Number 5, May 1999 , pp. 424-430(7)

Publisher: Blackwell Publishing

Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

Authors: Kaesemeyer W.H.; Caldwell R.B.; Huang J.; Caldwell R.W.

Source: Journal of the American College of Cardiology, Volume 33, Number 1, January 1999 , pp. 234-241(8)

Publisher: Elsevier

Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro - An unusual type of lipid antioxidant

Authors: Suzumura K.; Yasuhara M.; Tanaka K.; Suzuki T.

Source: Biochemical Pharmacology, Volume 57, Number 6, 15 March 1999 , pp. 697-703(7)

Publisher: Elsevier

Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits

Authors: Shiomi M.; Ito T.; Tsukada T.; Tsujita Y.; Horikoshi H.

Source: Atherosclerosis, Volume 142, Number 2, February 1999 , pp. 345-353(9)

Publisher: Elsevier